Skip to main content
Other
Originally Published 1 July 1999
Free Access

Blood Pressure and the Progression of Carotid Atherosclerosis in Middle-Aged Men

Abstract

Abstract—Elevated blood pressure has consistently been associated with increased prevalence of preclinical atherosclerosis and with increased risk of clinical atherosclerotic cardiovascular disease (CVD). However, there is no prospective evidence of the association between blood pressure and the progression of preclinical atherosclerosis. We therefore investigated the relationships of systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure to the 4-year increase in the measures of early carotid atherosclerosis, the mean and maximal common carotid intima-media thickness (IMT), assessed by B-mode ultrasonography, in 1026 men aged 42 to 60 years. Men with the SBP of <120, 120 to 126, 127 to 134, 135 to 143, and >143 mm Hg (fifths) had an increase in the mean IMT of 0.074, 0.090, 0.110, 0.136, and 0.158 mm per 4 years (P<0.001 for difference between groups, P<0.001 for linear trend) and in the maximal IMT of 0.212, 0.221, 0.279, 0.286, and 0.315 mm per 4 years, (P<0.001, P<0.001), respectively, adjusting for other atherosclerotic risk factors, including DBP. Also, pulse pressure, when adjusted for other risk factors including mean arterial pressure, was directly associated with the IMT increase. DBP was not independently related to the IMT increase. This is the first documentation to show that mildly elevated SBP and pulse pressure accelerate the progression of preclinical atherosclerosis. This study provides further evidence for the finding that systolic hypertension is a more important risk factor for atherosclerosis and consequent CVD than diastolic hypertension. Therefore, more attention should be paid to the level of SBP in the evaluation of CVD risk and in the treatment of hypertension.
Basic research has suggested that hypertension plays an important role in the pathogenesis of atherosclerosis.1 2 Indeed, elevated systolic blood pressure (SBP) and diastolic blood pressure (DBP) have consistently been associated with increased risk of atherosclerotic cardiovascular disease (CVD) in prospective population studies.3 4 5 Additional evidence for the role of hypertension as a predictor of CVD derives from randomized trials,6 7 8 9 in which the treatment of elevated blood pressure (BP) with antihypertensive drugs has reduced CVD risk. Even mildly elevated SBP and DBP have been related to increased CVD risk in prospective population studies.3 4 5 Support for this finding comes from randomized trials6 9 that have shown a large cardiovascular benefit from the treatment of uncomplicated mild hypertension.
Decisions about the initiation of antihypertensive medication have usually been based on the level of DBP.3 7 According to some prospective population studies,4 5 however, systolic hypertension may be a more important CVD risk factor than diastolic hypertension. Consistently, elevated SBP but not elevated DBP has been associated with increased prevalence of early atherosclerotic manifestations, including carotid intima-media thickening, in cross-sectional studies.10 11 12 13 Additional evidence for the role of systolic hypertension in CVD derives from a randomized trial, in which the treatment of elevated SBP with antihypertensive drugs slowed the progression of carotid stenosis14 and reduced CVD risk8 in older persons with isolated systolic hypertension. Some studies have also emphasized elevated pulse pressure as a risk factor for atherosclerosis11 12 13 and consequent CVD.15 16
There are no previous reports from prospective population studies of the association between BP and the progression of preclinical atherosclerosis. We therefore investigated the relationships of SBP, DBP, and pulse pressure to the 4-year increase in the measures of early carotid atherosclerosis, the mean and maximal intima-media thickness (IMT) in the common carotid arteries (CCAs), in a population-based sample of middle-aged men from eastern Finland.

Methods

Subjects

The subjects were participants in the Kuopio Ischemic Heart Disease Risk Factor Study (KIHD), which is an ongoing population study designed to investigate risk factors for CVD, atherosclerosis, and related outcomes in men from eastern Finland.17 The recruitment of the subjects has been explained in detail previously.17 The KIHD was approved by the Research Ethics Committee of the University of Kuopio, Kuopio, Finland. Each subject gave written informed consent to participate in the study. A total of 1229 men who had undergone ultrasound examination of the carotid arteries at the KIHD baseline between August 1986 and December 1989 were invited to participate in a 4-year follow-up study between March 1991 and December 1993. Of these men, 1038 (88.2%) participated, 107 refused, 52 could not participate because of death, severe illness, or relocation, and 32 could not be contacted. Average time to follow-up was 4.2 years (range 3.8 to 5.2 years). This study is based on data from the 1026 men who had complete information on BP and carotid atherosclerosis. Of these men, 73 had been in the pravastatin treatment group in the Kuopio Atherosclerosis Prevention Study (KAPS) for 3 years.18 We included these men in the present study because the association between BP and atherosclerotic progression remained similar regardless of whether these men were included.

Measurement of BP

BP was measured with a random-zero mercury sphygmomanometer (Hawksley) between 8:00 and 10:00 am. The measurement protocol included a supine rest of 5 minutes, then 3 measurements with subjects in the supine position, 1 measurement with subjects in the standing position, and 2 measurements with subjects in the seated position at 5-minute intervals. The mean of all 6 values was used as a measure of BP in the present study.

Assessment of Carotid Atherosclerosis

The extent and severity of carotid atherosclerosis was assessed by high-resolution B-mode ultrasonography of the right and left CCA of a 1.0- to 1.5-cm section at the distal end of the CCA proximal to the carotid bulb as explained in detail previously.19 The mean and maximal IMT were used as the measures of carotid atherosclerosis in the present study. The mean IMT was calculated as the mean of ≈100 IMT estimates from the right and left CCA and was used as an overall measure of the atherosclerotic process. The maximal IMT was calculated as the average of the points of maximal thickness from the right and left CCA and was used as an indicator of the depth of intima-media protrusion into the lumen in this part of the CCA. The baseline ultrasonographic findings were classified into 4 categories according to their severity: (1) no atherosclerotic lesion, (2) intima-media thickening (a distance of >1.0 mm between the lumen/intima and the media/adventitia interfaces), (3) a nonstenotic plaque (a distinct area of mineralization or focal protrusion into the lumen), and (4) a large, stenotic plaque (obstruction of >20% of the lumen diameter).19

Assessment of Covariates

The examination protocol,17 the assessment of medical history, medications, cigarette smoking, the dietary intake of iron and vitamin C, alcohol consumption,20 maximal oxygen uptake (V̇o2 max),21 body mass index (BMI), waist-to-hip ratio,22 and hair mercury content20 have been described previously. The collection of blood specimens and the measurement of serum lipids,20 blood glucose, serum insulin,22 and plasma fibrinogen20 have been explained previously.

Statistical Methods

The baseline associations of BP with covariates were investigated with univariate regression analysis. The strongest baseline risk factors for the IMT increase were determined by entering each variable individually into the multivariate regression model with the technical covariates (examination years, the zooming depth at baseline for right and left side, the baseline mean or maximal IMT, sonographer, follow-up time, and pravastatin treatment in the KAPS). The heterogeneity of the means of the IMT increase across the fifths of BP was examined with covariance analysis, and the linear trend was tested with multivariate regression analysis. All analyses included the technical covariates. Other covariates were selected based on their statistical significance (P<0.20) versus all variables shown in Table 1 and were entered into the same step-up multivariate regression model. These variables included age, treatment for dyslipidemia, cigarette smoking, iron and vitamin C intake, V̇o2 max, hair mercury content, serum HDL cholesterol, and waist-to-hip ratio. All statistical analyses were conducted with procedures from SAS, version 6.09, installed on an IBM RS/6000.

Results

BP and Other Baseline Characteristics

Baseline characteristics are shown in Table 1. SBP had unadjusted direct associations with BMI, waist-to-hip ratio, fasting serum insulin, serum triglycerides (P<0.001); the baseline mean IMT and type 2 diabetes (P=0.001); age (P=0.005); the baseline maximal IMT (P=0.006); and serum apolipoprotein B (P=0.01). SBP had inverse relationships with V̇o2 max (P<0.001) and treatment for dyslipidemia (P=0.02). DBP had unadjusted direct associations with BMI, waist-to-hip ratio, fasting serum insulin, serum triglycerides (P<0.001); and serum apolipoprotein B (P=0.001). DBP had inverse relationships with iron intake (P=0.003); V̇o2 max (P=0.005); treatment for dyslipidemia (P=0.02); vitamin C intake and baseline maximal IMT (P=0.04); and age (P=0.05).

Strongest Baseline Risk Factors for 4-Year Increase in the Mean and Maximal IMT

The strongest baseline risk factors for the IMT increase were high hair mercury content, elevated pulse pressure, high age, low V̇o2 max, treatment for dyslipidemia, elevated SBP, cigarette smoking, increased plasma fibrinogen, high iron intake, and high waist-to-hip ratio (Table 2).

Baseline BP and 4-Year Increase in the Mean and Maximal IMT

SBP had a strong, direct, and graded association with the increase in the mean and maximal IMT when adjusted for other risk factors (Table 3). These relationships were even stronger after further adjustment for DBP. The difference in the increase in the mean IMT between the highest and lowest fifth was 57% adjusted for other risk factors and 114% after additional adjustment for DBP. The respective differences in the increase in the maximal IMT were 33% and 49%. DBP had a weak, direct association with the increase in the maximal IMT when adjusted for other risk factors but not after further adjustment for SBP (Table 3). DBP was not related to the increase in the mean IMT. SBP was associated directly with the increase in the mean and maximal IMT at each level of DBP, whereas DBP had no consistent relationship with the IMT increase at different levels of SBP (Figure). Pulse pressure was directly associated with the increase in the mean and maximal IMT when adjusted for other risk factors (Table 3). These relationships were slightly weaker after additional adjustment for mean arterial pressure. The difference in the increase in the mean IMT between the highest and lowest fifth was 64% when adjusted for other risk factors and 57% when also adjusted for mean arterial pressure. The respective differences in increase in maximal IMT were 30% and 22%.

Baseline IMT and the 4-Year Increase in BP

The mean IMT had an unadjusted direct association with the increase in SBP (P=0.005) and pulse pressure (P<0.001). Also, the maximal IMT had an unadjusted direct relationship with the increase in SBP (P=0.01) and pulse pressure (P<0.001). These associations disappeared after further adjustment for age. The IMT was not related to the change in DBP.

Discussion

This 4-year follow-up study in middle-aged men provides the first prospective evidence that mildly elevated SBP and pulse pressure accelerate the progression of preclinical atherosclerosis, quantified by the mean and maximal IMT in the CCAs. SBP had a strong, graded, and direct association with the IMT increase regardless of the level of DBP, whereas DBP had no relationship with the IMT increase when controlled for SBP. Intima-media thickening started to accelerate at the SBP of approximately 120 mm Hg and at the pulse pressure of ≈36 mm Hg. Interestingly, intima-media thickening was the most rapid in men with SBP of >140 mm Hg and DBP of <85 mm Hg.
Taken together with prospective studies of CVD events,3 4 5 the present study shows that even mildly elevated BP is a risk factor for atherosclerosis and consequent CVD. Similar to the results of cross-sectional studies of early atherosclerotic manifestations10 11 12 13 and prospective studies of CVD events,4 5 15 16 our findings suggest that systolic hypertension is a more important risk factor for atherosclerosis and CVD than diastolic hypertension and that elevated pulse pressure also increases the risk of atherosclerotic CVD. Interestingly, some other studies have suggested that elevated SBP is also a risk factor for early atherosclerosis in populations with a high prevalence of hypertension but a relatively low prevalence of atherosclerosis and hypercholesterolemia, such as in the Japanese.23 Our findings provide one explanation for the effectiveness of antihypertensive medication in reducing CVD risk in persons with uncomplicated mild hypertension6 9 or isolated systolic hypertension.8 They also are in agreement with the reduced treatment goals for hypertension recommended by the Joint National Committee24 and the World Health Organization/International Hypertension Society.25
Previous studies11 12 13 have not been able to draw a conclusion about the time order of the relationship between BP and atherosclerosis due to their cross-sectional study design. In our prospective study, baseline SBP and pulse pressure were directly and independently associated with the IMT increase, which suggests that systolic hypertension and high pulse pressure are true atherosclerotic risk factors. However, baseline IMT was also associated directly with the increase in SBP and pulse pressure. Such a reciprocal relationship indicates a vicious cycle between baseline BP and IMT in the central conduit vessels. In other words, the increase in IMT and artery wall stiffness is associated with elevated SBP and pulse pressure at baseline due to the relative stiffness of the artery wall, and further stiffening would be related to a greater increase in BP. However, this phenomenon appears to occur mainly in older individuals, because the association between baseline IMT and the increase in BP disappeared when data were controlled for age.
In the Systolic Hypertension in the Elderly Program (SHEP),14 the progression of carotid stenosis, quantified by blood flow velocity and extent of plaque, was slower in the diuretic and/or β-blocker group than in the placebo group, which suggests a causal association between systolic hypertension and atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)26 did not, however, provide evidence for a causal relationship, because the carotid IMT increased less over the first 6 months of the trial in spite of a slightly higher SBP in the isradipine group than in the hydrochlorothiazide group. Ongoing trials27 will provide further information about the effect of lowered BP on intima-media thickening.
Carotid IMT, assessed by ultrasonography, has been regarded as a valid indicator of generalized atherosclerosis, because it has been related to atherosclerotic risk factors, coronary and peripheral atherosclerosis, and the risk of coronary and cerebrovascular events.19 28 29 30 However, it has been criticized as an indicator of atherosclerosis, because the intima cannot be discriminated from the media using ultrasonography. Thus, it is likely that the IMT increase observed in our study is not only due to atherosclerotic intimal thickening but also due to medial hypertrophy caused by the hemodynamic stimulation of a progressive increase in SBP, pulse pressure, or arterial diameter over time.
Hypertension could cause atherosclerosis through a number of plausible mechanisms, which have been reviewed in detail previously.1 2 Briefly, hypertension has been associated with (1) impaired endothelium-dependent arterial relaxation, (2) enhanced monocyte and lymphocyte adherence to the endothelium and migration into the intima, (3) enhanced macrophage accumulation in the intima, (4) stimulated growth factor and cytokine expression, (5) stimulated smooth-muscle cell proliferation, (6) increased plaque cellularity, (7) increased susceptibility to intimal tears due to increased medial collagen synthesis and reduced arterial wall elasticity, (8) increased vascular oxidative stress and oxygen-free radical production by the arterial wall, and (9) increased hypoxia caused by increased diffusion distances due to intimal and medial thickening.
The results of the present study are important from both a clinical and public health viewpoint. This is the first documentation that mildly elevated SBP and pulse pressure accelerate the progression of preclinical atherosclerosis in middle-aged men with increased CVD risk. This study provides further evidence for the finding that systolic hypertension is a more important risk factor for atherosclerosis and consequent CVD than is diastolic hypertension. Therefore, more attention should be paid to the level of SBP in the evaluation of CVD risk and in the treatment of hypertension.
Figure 1. The 4-year increase in the mean and maximal CCA IMT according to SBP and DBP adjusting for examination years, the zooming depth at baseline for right and left side, the baseline mean or maximal IMT, sonographer, follow-up time and pravastatin treatment in the KAPS.
Table 1. Baseline Characteristics of Subjects
CharacteristicMeanSDRange
Age, y52.06.742.0–61.3
BMI, kg/m226.73.418.8–40.3
Waist-to-Hip Ratio0.940.060.75–1.51
SBP, mm Hg131.816.188.7–211.7
DBP, mm Hg87.410.258.7–129.0
Pulse pressure, mm Hg44.410.922.7–111.7
Cigarette smoking, pack-years7.615.30.0–117.0
Dietary intake of iron, mg/d18.76.06.9–56.9
Dietary intake of vitamin C, mg/d86.353.36.6–550.4
Hair mercury content,1 μg/g1.811.960.0–23.30
o2max, L/min2.490.620.47–5.46
Serum LDL cholesterol, mmol/L3.860.930.68–8.46
Serum HDL cholesterol, mmol/L1.300.300.58–2.78
Serum triglycerides, mmol/L1.440.870.25–7.84
Serum apolipoprotein B, g/L1.010.230.19–2.08
Fasting serum insulin, mU/L10.85.91.0–50.0
Plasma fibrinogen, g/L3.000.561.74–6.71
Mean common carotid IMT, mm0.770.170.42–2.12
Maximal common carotid IMT, mm0.950.240.54–2.71
Treated for hypertension, %20.6%  
β-blockers, %15.2%  
Diuretics, %3.1%  
Treated for dyslipidemia, %1.1%  
Type 2 diabetes, %3.8%  
Advanced atherosclerosis, %131.0%  
1
Defined as stenotic plaque (>20 percent of the lumen diameter obstructed) or nonstenotic plaque (distinct mineralization or focal protrusion into the lumen).
Table 2. Strongest Baseline Risk Factors for a 4-Year Increase in Mean and Maximal CCA IMT
Risk FactorsIncrease in Mean IMT (mm/4 y)  Increase in Maximal IMT (mm/4 y)  
 Multivariate Regression Coefficient PMultivariate Regression Coefficient P
 Original Units (95% CI)Standardized Original Units (95% CI)Standardized 
Hair mercury content (μg/g)0.010 (0.006, 0.015)0.136<0.0010.011 (0.005, 0.017)0.107<0.001
Pulse pressure (mm/Hg)0.002 (0.0009, 0.002)0.125<0.0010.002 (0.001, 0.003)0.111<0.001
Age (y)0.003 (0.001, 0.004)0.120<0.0010.002 (0.0004, 0.004)0.0770.02
o2max (L/min)−0.027 (−0.041, −0.013)−0.113<0.001−0.039 (−0.059, −0.019)−0.118<0.001
Treatment for dyslipidemia (yes vs no)0.150 (0.068, 0.233)0.105<0.0010.166 (0.049, 0.282)0.0830.006
SBP (mm Hg)0.001 (0.0004, 0.001)0.100<0.0010.001 (0.0006, 0.002)0.109<0.001
Cigarette smoking (pack-years)0.001 (0.0002, 0.001)0.0790.010.001 (0.0003, 0.002)0.0840.008
Plasma fibrinogen (g/L)0.020 (0.005, 0.036)0.0760.010.029 (0.007, 0.051)0.0780.01
Dietary intake of iron (g/d)0.002 (0.0003, 0.003)0.0690.020.002 (−0.0003, 0.004)0.0490.10
Waist-to-hip ratio0.166 (0.020, 0.313)0.0680.030.252 (0.047, 0.457)0.0740.02
From linear forced regression models, including examination years, the zooming depth at baseline for right and left side, the baseline mean or maximal IMT, sonographer, follow-up time, and pravastatin treatment in KAPS.
Table 3. Four-Year Increase in Mean and Maximal CCA IMT (in Fifths) of SBP, DBP, and Pulse Pressure
 Increase in Mean IMT(mm/4 y), mean (95% CI) Increase in Maximal IMT (mm/4 y), mean (95% CI) 
SBP, mm HgAdjusted for covariates1Adjusted also for DBPAdjusted for covariates1Adjusted also for DBP
<1200.090 (0.072, 0.112)0.074 (0.072–0.112)0.226 (0.203, 0.256)0.212 (0.203–0.256)
120–1260.097 (0.074, 0.116)0.090 (0.074–0.116)0.228 (0.190, 0.253)0.221 (0.190–0.253)
127–1340.110 (0.092, 0.123)0.110 (0.092–0.123)0.280 (0.254, 0.300)0.279 (0.254–0.300)
135–1430.129 (0.113, 0.146)0.136 (0.113–0.146)0.280 (0.254, 0.310)0.286 (0.254–0.310)
>1430.141 (0.118, 0.169)0.158 (0.118–0.169)0.300 (0.272, 0.335)0.315 (0.272–0.335)
Difference between fifthsP=0.001P<0.001P<0.001P<0.001
Linear trendP<0.001P<0.001P<0.001P<0.001
     
DBP, mm HgAdjusted for covariates1Adjusted also for SBPAdjusted for covariates1Adjusted also for SBP
<790.100 (0.068–0.112)0.121 (0.068–0.112)0.227 (0.185–0.246)0.255 (0.185–0.246)
79–850.115 (0.097–0.139)0.122 (0.097–0.139)0.260 (0.237–0.290)0.270 (0.237–0.290)
86–900.112 (0.086–0.127)0.114 (0.086–0.127)0.275 (0.236–0.299)0.277 (0.236–0.299)
91–960.124 (0.111–0.146)0.116 (0.111–0.146)0.290 (0.271–0.325)0.281 (0.271–0.325)
>960.118 (0.107–0.145)0.095 (0.107–0.145)0.266 (0.249–0.297)0.235 (0.249–0.297)
Difference between fifthsP=0.51P=0.50P=0.03P=0.13
Linear trendP=0.15P=0.20P=0.01P=0.99
     
Pulse pressure, mm HgAdjusted for covariates1Adjusted also for MAPAdjusted for covariates1Adjusted also for MAP
<360.088 (0.076–0.111)0.090 (0.076–0.111)0.231 (0.214–0.263)0.239 (0.214–0.263)
36–410.111 (0.093–0.128)0.112 (0.093–0.128)0.261 (0.235–0.285)0.264 (0.235–0.285)
42–450.108 (0.091–0.126)0.108 (0.091–0.126)0.253 (0.228–0.279)0.254 (0.228–0.279)
46–510.117 (0.093–0.137)0.116 (0.093–0.137)0.269 (0.234–0.299)0.266 (0.234–0.299)
>510.144 (0.115–0.165)0.141 (0.115–0.165)0.301 (0.265–0.328)0.291 (0.265–0.328)
Difference between fifthsP=0.001P=0.03P=0.007P=0.22
Linear trendP=0.001P=0.004P=0.002P=0.04
1
From covariance models, including age, examination years, the zooming depth at baseline for right and left side, the baseline mean or maximal IMT, sonographer, follow-up time, pravastatin treatment in KAPS, treatment for dyslipidemia, cigarette smoking, dietary intake of iron and vitamin C, V̇o2max, hair mercury content, serum HDL cholesterol, and waist-to-hip ratio. MAP indicates mean arterial pressure.

Acknowledgments

We thank Kimmo Ronkainen for data analyses and Kristiina Nyyssönen and Kari Seppänen for supervising laboratory measurements. The KIHD was supported by grants from the Academy of Finland, the Finnish Ministry of Education and the National Heart, Lung, and Blood Institute of the USA (grant HL-44199). Timo Lakka was supported by a grant from the Yrjö Jahnsson Foundation. Jukka T. Salonen was an Academy Professor of the Academy of Finland.

References

1.
Alexander RW. Theodore Cooper Memorial Lecture: hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155–161.
2.
Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension: potential mechanisms and clinical implications. Arch Intern Med. 1996;156:1952–1956.
3.
MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Codwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–774.
4.
Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risk. Arch Intern Med. 1993;153:598–615.
5.
Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571–576.
6.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, I: reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562–2571.
7.
Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827–838.
8.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–3264.
9.
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755–1762.
10.
Salonen R, Salonen JT. Determinants of carotid intima-media thickness: a population-based ultrasonographic study in eastern Finnish men. J Intern Med. 1991;229:225–231.
11.
Psaty BM, Furberg CD, Kuller LH, Borhani NO, Rautaharju PM, O’Leary DH, Bild DE, Robbins J, Fried LP, Reid C. Isolated systolic hypertension and subclinical cardiovascular disease in the elderly: initial findings from the Cardiovascular Health Study. JAMA. 1992;268:1287–1291.
12.
Bots ML, Hofman A, de Bruyn AM, de Jong PTVM, Grobbee DE. Isolated systolic hypertension and vessel wall thickness of the carotid artery: the Rotterdam Elderly Study. Arterioscler Thromb. 1993;13:64–69.
13.
Arnett DK, Tyroler HA, Burke G, Hutchinson R, Howard G, Heiss G. Hypertension and subclinical carotid artery atherosclerosis in blacks and whites: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 1996;156:1983–1989.
14.
Sutton-Tyrrell K, Wolfson SK, Kuller LH. Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic blood pressure. Stroke. 1994;25:44–50.
15.
Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395–401.
16.
Benetos A, Safar M, Rudnichi A, Smulyan H, Richard J-L, Ducimetiere P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension. 1997;30:1410–1415.
17.
Salonen JT. Is there a continuing need for longitudinal epidemiologic research: the Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res. 1988;20:46–50.
18.
Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758–1764.
19.
Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87 Suppl II:II-56–II-65.
20.
Salonen JT, Seppänen K, Nyyssönen K, Korpela H, Kauhanen J, Kantola M, Tuomilehto J, Esterbauer H, Tatzber F, Salonen R. Intake of mercury from fish, lipid peroxidation and the risk of myocardial infarction and coronary, cardiovascular and any death in Eastern Finnish men. Circulation. 1995;91:645–655.
21.
Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. N Engl J Med. 1994;330:1549–1554.
22.
Salonen JT, Lakka TA, Lakka H-M, Valkonen V-P, Everson SA, Kaplan GA. Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men. Diabetes. 1998;47:270–275.
23.
Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. Stroke. 1997;28:518–525.
24.
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446.
25.
Zanchetti A. Guidelines for the management of hypertension: the World Health Organization/International Society of Hypertension view: World Health Organization: International Society of Hypertension. J Hypertens Suppl. 1995;13:119–122.
26.
Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond G. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA. 1996;276:785–791.
27.
Zanchetti A. Trials investigating the anti-atherosclerotic effects of antihypertensive drugs. J Hypertens Suppl.1996;14:S77–S80.
28.
Crouse JR, Thompson CJ. An evaluation of methods for imaging and quantifying coronary and carotid lumen stenosis and atherosclerosis. Circulation. 1993;87(suppl II):II-17–II-33.
29.
Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson CJ, Heiss G, Crouse JR III. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case-control study. Circulation. 1990;82:1230–1242.
30.
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and the risk of stroke and myocardial infarction: The Rotterdam Study. Circulation. 1997;96:1432–1437.

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.

Information & Authors

Information

Published In

Go to Hypertension
Go to Hypertension
Hypertension
Pages: 51 - 56
PubMed: 10406823

History

Received: 24 November 1998
Revision received: 24 December 1998
Accepted: 1 March 1999
Published online: 1 July 1999
Published in print: July 1999

Permissions

Request permissions for this article.

Keywords

  1. atherosclerosis
  2. ultrasonography
  3. blood pressure
  4. hypertension, mild
  5. population studies
  6. pulse pressure

Authors

Affiliations

Timo A. Lakka
From the Research Institute of Public Health, University of Kuopio, Kuopio, Finland (T.A.L., J.T.S., R.S.), and the Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Mich (G.A.K.).
Riitta Salonen
From the Research Institute of Public Health, University of Kuopio, Kuopio, Finland (T.A.L., J.T.S., R.S.), and the Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Mich (G.A.K.).
George A. Kaplan
From the Research Institute of Public Health, University of Kuopio, Kuopio, Finland (T.A.L., J.T.S., R.S.), and the Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Mich (G.A.K.).
Jukka T. Salonen
From the Research Institute of Public Health, University of Kuopio, Kuopio, Finland (T.A.L., J.T.S., R.S.), and the Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Mich (G.A.K.).

Notes

Correspondence to Timo A. Lakka, MD, PhD, Research Institute of Public Health, University of Kuopio, PO Box 1627, 70211 Kuopio, Finland. E-mail [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

  1. Non-linear association and benchmark dose of blood pressure on carotid artery intima-media thickening in a general population of southern China, Frontiers in Cardiovascular Medicine, 11, (2024).https://doi.org/10.3389/fcvm.2024.1325947
    Crossref
  2. The Association between Cardiovascular Risk Factors and Carotid Intima-Media Thickness in 42,726 Adults in UK Biobank: A Cross-Sectional Study, Journal of Cardiovascular Development and Disease, 10, 9, (358), (2023).https://doi.org/10.3390/jcdd10090358
    Crossref
  3. Cumulative burden and trajectories of body mass index and blood pressure from childhood and carotid intima-media thickness in young adulthood, Preventive Medicine, 177, (107747), (2023).https://doi.org/10.1016/j.ypmed.2023.107747
    Crossref
  4. Atherosklerose-Risikofaktoren, Atherosklerose-Pathogenese und mikrovaskuläre Dysfunktion, (9-47), (2023).https://doi.org/10.1007/978-3-031-31766-8_2
    Crossref
  5. Remodeling of Retinal Arterioles and Carotid Arteries in Heart Failure Development—A Preliminary Study, Journal of Clinical Medicine, 11, 13, (3721), (2022).https://doi.org/10.3390/jcm11133721
    Crossref
  6. Sex -Specific Differences in the Association Between Metabolic Syndrome and Carotid Intima-Media Thickness Among a Low-Income Population in China: A Cross-Sectional Study, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 14, (3263-3272), (2021).https://doi.org/10.2147/DMSO.S313702
    Crossref
  7. Technical Validation and Usability of a Portable Ultrasound-Based System for Carotid Assessment of Vascular Ageing: A Pilot Study, Heart, Lung and Circulation, 30, 11, (1734-1743), (2021).https://doi.org/10.1016/j.hlc.2021.06.530
    Crossref
  8. Direct and indirect effects of obesity on progression of carotid arterial injury in youth, Obesity, 29, 11, (1892-1898), (2021).https://doi.org/10.1002/oby.23265
    Crossref
  9. To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa, Journal of Global Health, 10, 1, (2020).https://doi.org/10.7189/jogh.10.010407
    Crossref
  10. Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials, Current Pharmaceutical Design, 26, 1, (11-24), (2020).https://doi.org/10.2174/1381612825666191213120339
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and All Supplements

PDF/ePub

View PDF/ePub

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to access the full text.

Purchase access to this article for 24 hours

Blood Pressure and the Progression of Carotid Atherosclerosis in Middle-Aged Men
Hypertension
  • Vol. 34
  • No. 1

Purchase access to this journal for 24 hours

Hypertension
  • Vol. 34
  • No. 1
Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Media

Figures

Other

Tables

Share

Share

Share article link

Share

Comment Response